Major Histocompatibility Complex 2019; 26 (1): 38 68 抄録集 17 2019 3 2 7 2 4 43 TEL 06 6962 7001 553 0003 2 1 7 TEL 06 6458 5821 38
17 MHC 2019; 26 (1) 参加費 1 2,000 2 1,000 3 3,000 会議等 1 3 2 13 00 13 10 2 3 212 00 13 00 3 3 2 17 20 会場地図 7 2 4 43 TEL 06 6962 7001 JR 350 m 39
MHC 2019; 26 (1) 17 プログラム 8 30 10 00 HLA 10 25 10 30 開会の挨拶 10 30 10 50 オープニングセミナー 44 HLA 10 50 11 30 一般演題 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) 40
17 MHC 2019; 26 (1) 11 30 12 00 一般演題 (2) 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) 12 00 13 00 ランチョンセミナー HLA I HLA II 後援 : 株式会社ベリタス 12 00 13 00 世話人会 13 00 13 10 総会 13 10 14 10 特別講演 HLA Killer immunoglobulin-like receptor KIR 41
MHC 2019; 26 (1) 17 14 10 15 40 シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 15 40 15 50 休憩 15 50 17 20 シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 17 20 意見交換会 10 30 42
17 MHC 2019; 26 (1) 10 30 10 50 オープニングセミナー 44 HLA 43
MHC 2019; 26 (1) 17 44 HLA 2018 10 44 ASHI, American Society for Histocompatibility and Immunogenetics 1 NGS Next Generation Sequencing 2 FcRn neonatal Fc receptor FcRn IgG IgG MHC I FcRn ph IgG IgA IgM 5 6 IgG 20 25 FcRn Rozanolixizumab I 3 CAR-T Chimeric antigen receptor T cell CAR-T T T CAR-T CTL 2017 B ALL 2018 DLBCL FDA 4 CRISPR-Cas9 Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 CRISPR-Cas9 DNA CRISPR-Cas9 PAM Hot topics Best poster Rheumatoid Arthritis, RA HLA- DRB1 71 K E DRB1*04:01 K71E RA 5 Non-HLA AMR Non-HLA MICA alloantibody AT1R, ETAR, Vimentin Autoantibody AT1R AMR 6 6-1 40 100 nm mrna mirna HLA BOS HLA Collagen-V Col-V 6-2 DNA cell free DNA, cfdna 44
17 MHC 2019; 26 (1) DNA 10 15 ng/ml 160 base pair 2 cfdna AMR 7 UNOS mtilda www.mtilda.com HLA UNOS API https:// developer.unos.org/ 45
MHC 2019; 26 (1) 17 10 50 11 30 一般演題 (1) 演題番号 1 ~ 4 46
17 MHC 2019; 26 (1) 1 HLA 1) 2) 1) 1) 1) 1) 1) 2) HLA Donor Specific Antibody DSA HLA 2018 4 12 HLA 301 2001 39 2001 2005 37 2006 2010 69 2011 2015 105 2016 2018 51 31 2001 Cw12 Cw14 B40 DR2 Cw11 DR6Y HLA DSA 47
MHC 2019; 26 (1) 17 2 LABScreen Single Antigen Beads HLA FCM 1) 1) 1) 1) 1)2) 1) 1) 2) HLA DSA FCM-XM 2015 12 2018 9 FCM-XM 382 LABScreen Single Antigen Beads DSA Mean Fluorescence Intensity Mean FI T cell B cell FCM-XM MFI 7 Class I B- cell FCM-XM DSA /FCM-XM 7 FCM-XM MFI Pt/ NC 2.2 3.5 >2 Class II HLA B-cell FCM-XM 24 310 334 DSA /FCM-XM DSA / FCM-XM 4 3 FCM-XM Pt/NC 2.1 2.3 >2 Class I DSA MFI T cell FCM-XM MFI R 2 =0.6559 Class II DSA MFI B cell FCM-XM MFI R 2 =0.8199 Class I HLA DSA T cell FCM-XM 23 345 368 DSA /FCM-XM 7 DSA MFI 748 2687 DSA /FCM-XM LABScreen Single Antigen Beads FCM-XM DSA non-hla 48
17 MHC 2019; 26 (1) 3 HLA Molecular Mismatch Method HLA class II de novo DSA dndsa 5 10 20 30% HLAclass II dndsa HLA-DQ HLA dndsa ABMR DSA ABMR HLA HLA HLA Molecular Mismatch Method HLA HLA class II dndsa 26 119 ABMR 14 non-abmr 12 2 HLA Cambridge HLA Immunogenicity algorithm EMSHMS Duquesnoy s HLA Structural Model Linear Epitope Conformational Epitope HLA C3d Luminex SAB Immucore HLA Epitope Registry HLA dndsa 26 119 DSA 50 69 DSA DSA EMS 31.7vs13.7 HMS 31.1vs12.0 DSA DSA EMS HMS DRB1 DRB3/4/5 DQA1/B1 EMS: 55.5vs21.4 HMS: 57.2vs19.5 P=0.0024, P=0.0018 HLA dndsa C3d ABMR 36 DSA C3d DSA 30 C3d DSA non-abmr 14 DSA C3d DSA C3d(+)DSA C3d( ) DSA EMS HMS 36.9vs23.8 37.5vs21.5 C3d(+)DSA C3d( )DSA P=0.0278, P=0.0112 HLA 1 HLA class II dndsa 2 HLA-DQ HLA class II 3 DSA 49
MHC 2019; 26 (1) 17 4 IgG HLA 1) 1) 2) 3) 3) 1) 3) 3) 3) 1) 1) 1) 1) 2) 3) NAIT NAIT HLA HPA HLA U N HLA A26/33 B61/58 U A2/33 B51/58 N A1/26 B37/61 2 1 HLA LABScreen Single Antigen OneLambda IgG A1 A2 B37 B51 U N U A2 B51 N A1 B37 A2 B51 A1 IgG A2 B51 A1 IgG1 IgG2 A2 B51 IgG1 IgG2 A1 N A2 B51 IgG3 IgG4 A2 B51 A1 IgG1 IgG2 HLA IgG3 NAIT HLA NAIT 50
17 MHC 2019; 26 (1) 11 30 12 00 一般演題 (2) 演題番号 5 ~ 7 51
MHC 2019; 26 (1) 17 5 HLA 1) 1) 1) 1) 1)2) 1) 1) 2) HLA HLA 2 HLA-C*01:02,*08:01 SSP HLA-C*01:02,*08:22 WAKFlow SSOP HLA 2018 2018 2018 1 1 30 HLA QCWS 2018 52
17 MHC 2019; 26 (1) 6 MEK 1) 1) 2) 1) 1) 1) 1) 3) 4) 1) 1) 2) 3) 4) 1 MEK mitogen-activated protein kinase T PPARγ MEK Streptozotocin H-2b MHC H-2d 28 MEK PCR T in vitro MEK MEK 30 vs. 11.5 ; p<0.01 MEK 7 T MEK Effector CD4+ T cell 44.0% vs. 58.3%; p=0.03 Naïve CD4+ T cell 42.2% vs. 30.5%; p=0.02 MEK IL-2/IFN-γ MEK 24 viability MEK naïve CD4 T Effector T MEK 53
MHC 2019; 26 (1) 17 7 HLA-F 1) 2) Daniel E Geraghty 3) 1) 1) 2) Fred Hutchinson Cancer Research Center 3) HLA-F HLA Ib HLA-F killer immunoglobulin like receptor (KIR)-3DL2 NK HLA-F mrna HLA-F KIR HLA-F 31 12 19 HLA-F No.1167 HLA-F 19 15 HLA-F t-test; p=0.0012 HLA-F HLA-F HLA-F 54
17 MHC 2019; 26 (1) 12 00 13 00 ランチョンセミナー HLA I HLA II 55
MHC 2019; 26 (1) 17 HLA 1) 2) 1) 2) 2018 4 HLA HLA HLA One Lambda Inc. 2 HLA HLA HLA Non-HLA LABScan Luminex LABScreen Autoantibody HLA CDC FCXM DSA Donor Specific Antibody FlowDSA- XM HLA A B C DR HLA Class II DP DQ HLA DP DQ 56
17 MHC 2019; 26 (1) 12 00 13 00 世話人会 13 00 13 10 総会 57
MHC 2019; 26 (1) 17 13 10 14 10 特別講演 HLA Killer immunoglobulin-like receptor KIR 58
17 MHC 2019; 26 (1) Killer immunoglobulin-like receptor KIR Natural killer NK killer immunoglobulin-like receptor KIR HLA KIR HLA NK KIR KIR Ruggeri, Science 2002 HIV AIDS KIR PCR KIR KIR KIR3DL1 HLA-B GD2 Forlenza, J Clin Oncol 2016 Boudreau, J Clin Oncol 2017 KIR KIR3DL1 Ureshino, Shindo, Cancer Immunol Res 2018 KIR KIR KIR 59
MHC 2019; 26 (1) 17 14 10 15 40 シンポジウム (1) 1 HLA 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) 3 HLA 60
17 MHC 2019; 26 (1) 1 HLA HLA HLA HLA HLA GVHD T GVHD anti-thymogloblin ATG cyclophosphamide CY HLA GVHD super high risk GVL graft versus leukemia ATG T GVHD / GVL GVHD HLA HLA HLA full allogeneicspousal preliminary data 1998 8 2017 12 HLA 654 40 14 69 / 323 148 119 64 92% 45 146 45 508 ATG 2.5 mg/kg tacrolimus (TAC)+ methylprednisolone (mpsl) 2 mg/kg+short-term MTX (smtx)+mycophenolate mofetil (MMF) 15 mg/kg TAC+mPSL 1 mg/kg 10 13 HLA 5 62% 31% 61
MHC 2019; 26 (1) 17 2 HLA HLA 1) 2) 3) 3) 4) 1) 2) HLA 3) 4) graft-versus-host disease, GVHD graft-versus-leukemia effect GVL GVHD Human leukocyte antigen, HLA HLA-A, -B, -C, -DRB1 HLA 6 HLA HLA HLA- A, -B, -C, -DRB1 HLA GVHD T HLA-A, -B, -C, -DRB1 1 3657 HLA HLA-A, -B, -C, -DRB1 8 HLA HLA HLA HLA private haplotype 0.005% 8 90% HLA 90% HLA 1731 47.8% 1914 52.9% HLA 1365 37.7% 1 1326 97.1% 39 2.9% 4 1 44.6% 41.7 47.4% 0 36.3% 20.5 52.3% p=0.12 4 DFS 1 42.0% 39.2 44.8% 0 29.9% 15.9 45.1%p=0.02 4 1 24.1% 21.7 26.5% 0 32.4% 17.8 48.0% p=0.18 1 33.9% 31.2 36.6% 0 37.7% 22.0 53.3% p=0.51 0 Grade II IV GVHD 100 1 46.1% 43.4 48.8% 0 34.2% 19.5 49.4% p=0.23 Grade III IV GVHD 100 1 17.1% 15.1 19.2% 0 13.2% 4.7 26.0% p=0.54 GVHD 4 1 62
17 MHC 2019; 26 (1) 36.8% 34.1 39.6% 0 32.1% 16.9 48.4% p=0.60 DFS PS 2 4 HR 2.54, 95%CI 1.89 3.43, vs PS 0 1 HR 0.81, 95%CI 0.66 1.00, vs TBI HR 2.21, 95%CI 1.82 2.69, vs 0 1 DFS HR 1.79, 95%CI: 1.10 2.69 HLA GVHD DFS HLA GVL HLA 63
MHC 2019; 26 (1) 17 3 HLA HLA HLA-A, -B, -DRB1 6 2 HLA-A, -B, -C, -DRB1 8 2 2 10 7 /kg CD34 HLA HLA 1237 2 HLA 1 HLA 0 HLA HLA-A, -B, -C, -DRB1 0 1 2 3 4 82 154 252 565 294 2 1 0 88% 82% 79% P=0.008 0 1 0.88 P=0.087 2 1.39 P=0.005 CD34 HLA 2 GVH Homo to hetero HLA 64
17 MHC 2019; 26 (1) 15 40 15 50 休憩 15 50 17 20 シンポジウム (2) HLA 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) 2 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) 65
MHC 2019; 26 (1) 17 1 de novo DSA 1) 2) 1) 1) 1) 1) 2) HLA de novo donor specific HLA antibodies: dn DSA chronic antibody mediated rejection: chronic AMR 2018 4 HLA chronic AMR chronic AMR HLA subclinical HLA chronic AMR 2013 1 2018 12 HLA 179 Flow PRA screening test LABScreen single antigen test dn DSA dn DSA dn DSA dn DSA 179 28 15.6% de novo DSA dn DSA 1 4.2% 3 8.5% 5 14.9% dn DSA HLA-class I +class II 7 HLA-DR DR+DQ 7 HLA-DQ 14 26 chronic AMR 9 T T cell mediated rejection: TCMR +AMR 1 subclinical AMR 3 13 Chronic AMR TCMR+AMR Rituximab Subclinical AMR 4 dn DSA chronic AMR 66
17 MHC 2019; 26 (1) 2 CDC T-cell MFI HLA FCM HLA A, B, C, DR, DQ, DP HLA CDC FCM HLA MFI<5000 80 2 DSA MFI CDC, FCM 103 4 DSA B 2 DQ 2 CDC FCM 2 4 2 DQ 2 FCM 1 2 AMR 2 HLA HLA A, B, DR FCM 67
MHC 2019; 26 (1) 17 3 de novo DSA 1) 2) 2) 2) 3) 3) 4) 4) 2) 2) 2) 5) 2) 1) 2) 3) 4) 5) HLA DSA DSA de novo DSA 2009 12 2016 12 SAB HLA 1 20 355 20 242 20 152 2015 10 2016 10 DSA 17% 38% DSA 50% F2 DSA 3% p=0.001 DSA 41.4% DSA 22.4% p=0.04 DSA DSA 34% DSA 51% DSA p=0.034 DSA p=0.0093 DSA DSA p=0.0431 DSA DSA DSA DSA 68